Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2025 value amounting to 0.04%.

  • Xeris Biopharma Holdings' Return on Capital Employed rose 2300.0% to 0.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.04%, marking a year-over-year increase of 2300.0%. This contributed to the annual value of 0.15% for FY2024, which is 300.0% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Return on Capital Employed is 0.04%, which was up 2300.0% from 0.04% recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Return on Capital Employed registered a high of 0.04% during Q3 2025, and its lowest value of 0.83% during Q4 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Return on Capital Employed value was 0.2% (recorded in 2023), while the average stood at 0.27%.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Return on Capital Employed skyrocketed by 5000bps in 2022, and later surged by 100bps in 2024.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Return on Capital Employed stood at 0.83% in 2021, then soared by 61bps to 0.33% in 2022, then skyrocketed by 42bps to 0.19% in 2023, then increased by 21bps to 0.15% in 2024, then skyrocketed by 127bps to 0.04% in 2025.
  • Its last three reported values are 0.04% in Q3 2025, 0.04% for Q2 2025, and 0.1% during Q1 2025.